GLP-2 TIRZ — 20 mg

The TIRZ abbreviation commonly indicates tirzepatide. Some research catalogs add GLP-2 to signal dual incretin activity, but this is not the scientific name of its receptor target. Pure Tested Peptides explicitly discusses this naming practice, while Lilly’s product information identifies tirzepatide as an agonist of GIP and GLP-1 receptors. Accordingly, this description concerns tirzepatide and must not be confused with the intestinal hormone glucagon-like peptide-2 or a GLP-2 receptor agonist.

Lilly describes an albumin-binding fatty-acid modification that prolongs circulation and connects receptor activation with reduced calorie intake, glucose-dependent insulin secretion and reduced glucagon secretion. In the SURMOUNT-1 trial, adults with obesity or overweight and a weight-related complication, but without diabetes, had substantially greater average weight reductions with tirzepatide than placebo over 72 weeks. These findings underpin research and commercial discussions of dual-incretin metabolic effects. The original Umbrella catalog review did not establish an exact GLP-2 TIRZ product match, so the compound interpretation is based on documented market terminology and developer science, not confirmation of the identity of an unspecified vial. This distinction preserves both the requested label and the correct biological mechanism.